U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846515) titled 'Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)' on Feb. 21.
Brief Summary: This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Gout
Arthritis, Gouty
Hyperuricemia
Gout Chronic
Intervention:
DRUG: AR882 50 mg
Solid Oral Capsule
DRUG: AR882 75 mg
Solid Oral Capsule
DRUG: Placebo
Matching Solid Oral Capsule Placebo
Recruitment Status: RECRUITING
Sponsor: Arthrosi Therapeutics
Disclaimer: Curated by HT Syndication....